

# Are brain cancer patients finally able to benefit from precision medicine approaches?

León Auditorium, Hall 7, IFEMA MADRID,  
Madrid, Spain



Friday 20 October 2023 | 10:15 – 11:45 CEST

## Agenda

- 10:15–10:25** **Introduction: The Sword of Damocles hanging over each patient**  
Carmen Balaña
- 10:25–10:45** **IDH Mutated Glioma: A decade's journey from bench to bedside**  
Tim Cloughesy
- 10:45–11:00** **Connecting the dots: Understanding recent clinical evidence in the framework of previous studies and current practice**  
Martin van den Bent
- 11:00–11:15** **The evolving paradigm for clinical management of glioma**  
Sara Erridge
- 11:15–11:30** **Navigating the paradigm shift: Thriving in the new era of glioma care**  
Ghazaleh Tabatabai
- 11:30–11:45** **Q&A Session**  
All

## Overview

Isocitrate dehydrogenase (IDH) mutations have been recognised as an oncogenic driver in gliomas for more than a decade.

IDH mutant gliomas are the most common adult, malignant primary brain tumours diagnosed in patients younger than 50, and these malignancies constitute an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumours, driving several therapeutically focused programs to improve diagnosis and treatment.

We cordially invite you to join us for this exciting symposium at ESMO 2023 which will review the latest data and the implications for patients with these challenging tumours.

This satellite symposium is initiated, organised, and funded by Servier.

**Please note that you will need to be registered to attend ESMO 2023 in order to participate in this symposium.**